Int J Med Sci 2017; 14(9):880-884. doi:10.7150/ijms.19620 This issue Cite

Research Paper

Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development

Bin Wang1, Ying-Erh Chou2,3, Ming-Yu Lien4,5, Chen-Ming Su6, Shun-Fa Yang3,7✉, Chih-Hsin Tang4,8✉

1. Department of Hepatobiliary Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
2. School of Medicine, Chung Shan Medical University, Taichung, Taiwan;
3. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan;
4. Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan;
5. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
6. Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
7. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan;
8. Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.

Citation:
Wang B, Chou YE, Lien MY, Su CM, Yang SF, Tang CH. Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. Int J Med Sci 2017; 14(9):880-884. doi:10.7150/ijms.19620. https://www.medsci.org/v14p0880.htm
Other styles

File import instruction

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the third most common cause of cancer mortality. In Taiwan, HCC is the second leading cause of cancer death. CCL4 (C-C chemokine ligand 4), is a macrophage inflammatory protein with a chief effect in inflammation and immune-regulation, and was documented in cancer progression by promoting instability in the tumor environment. Polymorphisms in chemokine genes help to determine host-pathogen interactions that influence chemokine levels. We investigated the effects of CCL4 gene polymorphisms on the risk of hepatocellular carcinoma (HCC) disease progression in a cohort of Taiwanese patients. We recruited total of 1,546 participants in current study, including 1,200 healthy control and 346 patients with HCC. Three single-nucleotide polymorphisms (SNPs) of the CCL4 gene were examined by a real-time PCR. We found that the A/G homozygotes of CCL4 rs10491121 polymorphism reduced the risks for HCC. On the other hand, AG and GA haplotypes of 2 CCL4 SNPs (rs1049112 and rs171915) also reduced the risks for HCC by 0.025 and 0.515 fold, respectively. The present report is the first time to examine the risk factors associated with CCL4 SNPs in HCC progression in Taiwan.

Keywords: CCL4, HCC, SNP, Susceptibility


Citation styles

APA
Wang, B., Chou, Y.E., Lien, M.Y., Su, C.M., Yang, S.F., Tang, C.H. (2017). Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. International Journal of Medical Sciences, 14(9), 880-884. https://doi.org/10.7150/ijms.19620.

ACS
Wang, B.; Chou, Y.E.; Lien, M.Y.; Su, C.M.; Yang, S.F.; Tang, C.H. Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. Int. J. Med. Sci. 2017, 14 (9), 880-884. DOI: 10.7150/ijms.19620.

NLM
Wang B, Chou YE, Lien MY, Su CM, Yang SF, Tang CH. Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. Int J Med Sci 2017; 14(9):880-884. doi:10.7150/ijms.19620. https://www.medsci.org/v14p0880.htm

CSE
Wang B, Chou YE, Lien MY, Su CM, Yang SF, Tang CH. 2017. Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. Int J Med Sci. 14(9):880-884.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image